@article{PAR00003201,
  title = {{O}n chikungunya acute infection and chloroquine treatment},
  author = {de {L}amballerie, {X}avier and {B}oisson, {V}. and {R}eynier, {J}. {C}. and {E}nault, {S}. and {C}harrel, {R}. {N}. and {F}lahault, {A}. and {R}oques, {P}. and {L}e {G}rand, {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{I}n recent issues, the efficacy of chloroquine (and the dosage that may be used) in the treatment of acute chikungunya infections was discussed. {W}e have conducted a double-blind placebo-controlled randomized trial on the {F}rench {R}eunion {I}sland ({I}ndian {O}cean), in which 27 patients received chloroquine and 27 patients received a placebo treatment. {T}he chloroquine treatment consisted of 600 mg at day 1, 600 mg at days 2 and 3, and 300 mg at days 4 and 5. {N}o significant difference between groups could be identified regarding the duration of febrile arthralgia or the decrease of viremia between day 1 and day 3. {H}owever, at day 200, patients who received chloroquine complained more frequently of arthralgia than those who received placebo (p < 0.01). {I}n conclusion, {O}ur results suggest that there is currently no justification for the use of chloroquine to treat acute chikungunya infections.},
  keywords = {{A}rbovirus(es) ; {C}hikungunya},
  booktitle = {},
  journal = {{V}ector-{B}orne and {Z}oonotic {D}iseases},
  volume = {8},
  numero = {6},
  pages = {837--839},
  ISSN = {1530-3667},
  year = {2008},
  DOI = {10.1089/vbz.2008.0049},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00003201},
}